Prosecution Insights
Last updated: April 19, 2026

Examiner: SCHWECHTER, BRANDON ROSS

Tech Center 1600 • Art Units: 1674

This examiner grants 0% of resolved cases

Performance Statistics

%
Allow Rate
-60.0% vs TC avg
6
Total Applications
Interview Lift
1175
Avg Prosecution Days
Based on 0 resolved cases, 2023–2026

Rejection Statute Breakdown

2.6%
§101 Eligibility
23.7%
§102 Novelty
26.3%
§103 Obviousness
44.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18355108 Macrophage Stimulating 1 Receptor (MST1R) Variants And Uses Thereof Non-Final OA Regeneron Pharmaceuticals, Inc.
18262543 PEPTIDE FOR PREVENTING AND TREATING FIBROSIS Non-Final OA SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
18345430 METHODS FOR THERAPY AND REHABILITATION OF MOVEMENT DISORDERS Non-Final OA City University of Hong Kong
18316084 INHIBITION AND REVERSION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BY ENDOTHELIAL CELL REGENERATION Non-Final OA Therapeutic Solutions International, Inc.
18272116 SYNERGISTIC EFFECT OF A FXR AGONIST AND IFN FOR THE TREATMENT OF HBV INFECTION Non-Final OA UNIVERSITÉ CLAUDE BERNARD LYON 1

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month